GlaxoSmithKline has signed a contract with Serenex to use its chemoproteomics technology as part of GSK drug discovery programs.

Terms were not disclosed.

The companies said the Serenex Proteome Mining and Functional Proteome Fractionation technology would be used to screen thousands of compounds at the same time.

“We believe our technologies are tremendous tools to accelerate the drug discovery and development process by providing higher quality, more comprehensive data more rapidly than standard screening approaches,” said Richard Kent, president and chief executive officer of Serenex, in a statement.